Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury · TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatSpinal cord injuryHemisection / partialSprague-DawleyFemaleAcute, for two days after injury
Model: T9-10 spinal cord dorsal hemisection
Acute MMP-9/2 inhibition with SB-3CT increased NG2+ progenitor proliferation, improved remyelination and locomotor and somatosensory recovery after spinal cord injury.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
RatTBIFluid percussionSprague-DawleyMalen = n=15 per group, three groupsIntraperitoneal50 mg/kg in 10% dimethyl sulfoxideFirst dose 30 min after injury
Model: Fluid percussion traumatic brain injury
SB-3CT improved motor and spatial learning performance and preserved hippocampal neurons after fluid percussion TBI compared with saline-treated injured rats.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
